Mark L. Baum
2013
In 2013, Mark L. Baum earned a total compensation of $5.5M as Chief Executive Officer at Imprimis Pharmaceuticals, a 316% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $125,000 |
|---|---|
| Option Awards | $1,401,624 |
| Salary | $296,850 |
| Stock Awards | $3,688,257 |
| Total | $5,511,731 |
Baum received $3.7M in stock awards, accounting for 67% of the total pay in 2013.
Baum also received $125K in non-equity incentive plan, $1.4M in option awards and $296.9K in salary.
Rankings
In 2013, Mark L. Baum's compensation ranked 1,106th out of 12,286 executives tracked by ExecPay. In other words, Baum earned more than 91.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,106 out of 12,286 | 91st |
Division Manufacturing | 358 out of 4,612 | 92nd |
Major group Chemicals And Allied Products | 95 out of 1,466 | 94th |
Industry group Drugs | 60 out of 1,160 | 95th |
Industry Pharmaceutical Preparations | 53 out of 890 | 94th |
Source: SEC filing on April 10, 2015.
Baum's colleagues
We found one more compensation record of an executive who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2013.
2013
Andrew Boll
Imprimis Pharmaceuticals
Chief Financial Officer
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019